{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:06:10Z","timestamp":1780657570694,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Ocular surface inflammation due to allergy and blepharitis can lead to corneal complications and visual impairment. The aim of this study is to evaluate the efficacy of a cyclosporin 0.1% topical treatment achieving steroid-sparing. Eighty pediatric patients with moderate and severe vernal and blepharitis-related keratoconjunctivitis were included. Symptoms (photosensitivity, itching, discharge, tearing), signs (corneal fluorescein staining, papillary hypertrophy) and patients\u2019 subjective assessment were evaluated during a 6-month follow-up. At the follow-up, all patients treated with topical cyclosporin showed a significant improvement in all subjective symptoms and objective signs (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The total number of courses of rescue steroids courses decreased from 3.71\u2009\u00b1\u20091.72 to 0.25\u2009\u00b1\u20090.49 at month 3 and to 0.13\u2009\u00b1\u20090.38 dropping bottle at month 6 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 at both time points). The 96.1% of the allergic cohort and 96.4% of the blepharitis cohort experienced a satisfactory good or rapid and good effect during the 6-month follow-up. The probability of needing rescue corticosteroids increased with an odds ratio of 1.98, (95% CI: 1.19\u20133.28, <jats:italic>p<\/jats:italic>\u2009=\u20090.008) for each unit increase in Oxford score when analysing the whole cohort. Topical cyclosporin seems to be very effective reducing the number of recurrences of corneal involvement and the need for steroid treatment.<\/jats:p>","DOI":"10.1038\/s41598-025-85256-z","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:04:23Z","timestamp":1738973063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Corticosteroid-sparing topical treatment with cyclosporin for juvenile keratoconjunctivitis"],"prefix":"10.1038","volume":"15","author":[{"given":"Amarilla","family":"Barcsay-Veres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Csorba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Illes","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Tothfalusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto Alexander","family":"Maneschg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"85256_CR1","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamaophthalmol.2021.1708","volume":"139","author":"SY Zhang","year":"2021","unstructured":"Zhang, S. Y. et al. Association of Allergic Conjunctivitis with Health-Related Quality of Life in Children and their parents. JAMA Ophthalmol. 139, 830\u2013837 (2021).","journal-title":"JAMA Ophthalmol."},{"key":"85256_CR2","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1111\/all.13786","volume":"74","author":"A Leonardi","year":"2019","unstructured":"Leonardi, A. et al. Management of ocular allergy. Allergy 74, 1611\u20131630 (2019).","journal-title":"Allergy"},{"key":"85256_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s12016-023-08970-4","volume":"65","author":"G Bruschi","year":"2023","unstructured":"Bruschi, G. et al. Vernal Keratoconjunctivitis: a systematic review. Clin. Rev. Allergy Immunol. 65, 277\u2013329 (2023).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"85256_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2017.08.037","volume":"78","author":"RL Gallo","year":"2018","unstructured":"Gallo, R. L. et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee. J. Am. Acad. Dermatol. 78, 148\u2013155 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"85256_CR5","first-page":"1","volume":"26","author":"CN Kang","year":"2021","unstructured":"Kang, C. N., Shah, M., Tan, J. & Rosacea An update in diagnosis, classification and management. Skin. Therapy Lett. 26, 1\u20138 (2021).","journal-title":"Skin. Therapy Lett."},{"key":"85256_CR6","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jaad.2020.01.077","volume":"82","author":"D Thiboutot","year":"2020","unstructured":"Thiboutot, D. et al. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee. J. Am. Acad. Dermatol. 82, 1501\u20131510 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"85256_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/ICU.0000000000000399","volume":"28","author":"ST Rousta","year":"2017","unstructured":"Rousta, S. T. Pediatric blepharokeratoconjunctivitis: is there a \u2018right\u2019 treatment? Curr. Opin. Ophthalmol. 28, 449\u2013453 (2017).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"85256_CR8","unstructured":"N\u00e9meth, J., Barcsay-Veress, A., Nagy, Z. & Temesv\u00e1ri, E. (eds) (Gy. P\u00f3nyai) 377\u2013388 (Medicina, 2021)."},{"key":"85256_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1755-3768.2008.01347.x","volume":"87","author":"S Kumar","year":"2009","unstructured":"Kumar, S. Vernal keratoconjunctivitis: a major review. Acta Ophthalmol. 87, 133\u2013147 (2009).","journal-title":"Acta Ophthalmol."},{"key":"85256_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1600-0420.2005.00622.x","volume":"84","author":"A Leonardi","year":"2006","unstructured":"Leonardi, A. et al. Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study. Acta Ophthalmol. Scand. 84, 406\u2013410 (2006).","journal-title":"Acta Ophthalmol. Scand."},{"key":"85256_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00347-014-3184-z","volume":"112","author":"U Pleyer","year":"2015","unstructured":"Pleyer, U. & Leonardi, A. [Vernal Keratoconjunctivitis] Ophthalmologe 112, 177\u2013189 ; (2015). quiz 190\u2009\u2013\u2009171.","journal-title":"[Vernal Keratoconjunctivitis] Ophthalmologe"},{"key":"85256_CR12","first-page":"544","volume":"8","author":"A Arman","year":"2015","unstructured":"Arman, A., Demirseren, D. D. & Takmaz, T. Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline. Int. J. Ophthalmol. 8, 544\u2013549 (2015).","journal-title":"Int. J. Ophthalmol."},{"key":"85256_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bjd.17590","volume":"181","author":"EJ van Zuuren","year":"2019","unstructured":"van Zuuren, E. J. et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br. J. Dermatol. 181, 65\u201379 (2019).","journal-title":"Br. J. Dermatol."},{"key":"85256_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/ddg.14849","volume":"20","author":"BM Clanner-Engelshofen","year":"2022","unstructured":"Clanner-Engelshofen, B. M. et al. S2k guideline: Rosacea. J. Dtsch. Dermatol. Ges. 20, 1147\u20131165 (2022).","journal-title":"J. Dtsch. Dermatol. Ges"},{"key":"85256_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/ceo.13900","volume":"49","author":"S Tavassoli","year":"2021","unstructured":"Tavassoli, S., Wong, N. & Chan, E. Ocular manifestations of rosacea: a clinical review. Clin. Exp. Ophthalmol. 49, 104\u2013117 (2021).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"85256_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1556\/650.2019.31265","volume":"160","author":"A Csorba","year":"2019","unstructured":"Csorba, A., Soproni, A., Maneschg, O., Nagy, Z. Z. & Szamosi, A. [Application of corticosteroid eye drops for allergic eye diseases in children]. Orv Hetil. 160, 329\u2013337 (2019).","journal-title":"Orv Hetil"},{"key":"85256_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","volume":"25","author":"CN McGhee","year":"2002","unstructured":"McGhee, C. N., Dean, S. & Danesh-Meyer, H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 25, 33\u201355 (2002).","journal-title":"Drug Saf."},{"key":"85256_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/ICU.0000000000000706","volume":"31","author":"TK Redd","year":"2020","unstructured":"Redd, T. K. & Seitzman, G. D. Ocular rosacea. Curr. Opin. Ophthalmol. 31, 503\u2013507 (2020).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"85256_CR19","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1136\/bjo.2007.117812","volume":"92","author":"D Bremond-Gignac","year":"2008","unstructured":"Bremond-Gignac, D. et al. Prevalence of vernal keratoconjunctivitis: a rare disease? Br. J. Ophthalmol. 92, 1097\u20131102 (2008).","journal-title":"Br. J. Ophthalmol."},{"key":"85256_CR20","first-page":"e2021517","volume":"92","author":"G Brindisi","year":"2021","unstructured":"Brindisi, G. et al. Vernal keratoconjunctivitis: state of art and update on treatment. Acta Biomed. 92, e2021517 (2021).","journal-title":"Acta Biomed."},{"key":"85256_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ophtha.2015.07.012","volume":"123","author":"D Bremond-Gignac","year":"2016","unstructured":"Bremond-Gignac, D. et al. Atopic keratoconjunctivitis in children: clinical features and diagnosis. Ophthalmology 123, 435\u2013437 (2016).","journal-title":"Ophthalmology"},{"key":"85256_CR22","doi-asserted-by":"publisher","first-page":"e14987","DOI":"10.1111\/ijcp.14987","volume":"75","author":"C Cagini","year":"2021","unstructured":"Cagini, C. et al. Kinetics of hydrocortisone sodium phosphate penetration into the human aqueous humor after topical application. Int. J. Clin. Pract. 75, e14987 (2021).","journal-title":"Int. J. Clin. Pract."},{"key":"85256_CR23","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s10792-022-02608-8","volume":"43","author":"X Zhang","year":"2023","unstructured":"Zhang, X., Huang, F., Qiu, J., Yang, Y. & Zhang, C. Corneal biomechanical properties in vernal keratoconjunctivitis and its subtypes: a preliminary study. Int. Ophthalmol. 43, 2083\u20132090 (2023).","journal-title":"Int. Ophthalmol."},{"key":"85256_CR24","doi-asserted-by":"publisher","first-page":"e1361574","DOI":"10.1080\/19381980.2017.1361574","volume":"9","author":"BM Rainer","year":"2017","unstructured":"Rainer, B. M., Kang, S. & Chien, A. L. Rosacea: Epidemiology, pathogenesis, and treatment. Dermatoendocrinol 9, e1361574 (2017).","journal-title":"Dermatoendocrinol"},{"key":"85256_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0002-9394(99)00295-0","volume":"129","author":"A Leonardi","year":"2000","unstructured":"Leonardi, A. et al. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am. J. Ophthalmol. 129, 151\u2013158 (2000).","journal-title":"Am. J. Ophthalmol."},{"key":"85256_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.alit.2020.05.003","volume":"69","author":"J Shoji","year":"2020","unstructured":"Shoji, J. Ocular allergy test and biomarkers on the ocular surface: clinical test for evaluating the ocular surface condition in allergic conjunctival diseases. Allergol. Int. 69, 496\u2013504 (2020).","journal-title":"Allergol. Int."},{"key":"85256_CR27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/pai.12197","volume":"25","author":"P Vichyanond","year":"2014","unstructured":"Vichyanond, P., Pacharn, P., Pleyer, U. & Leonardi, A. Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes. Pediatr. Allergy Immunol. 25, 314\u2013322 (2014).","journal-title":"Pediatr. Allergy Immunol."},{"key":"85256_CR28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jtos.2020.09.009","volume":"19","author":"A Leonardi","year":"2021","unstructured":"Leonardi, A. et al. Conjunctival transcriptome analysis reveals the overexpression of multiple pattern recognition receptors in vernal keratoconjunctivitis. Ocul Surf. 19, 241\u2013248 (2021).","journal-title":"Ocul Surf."},{"key":"85256_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ophtha.2018.12.027","volume":"126","author":"A Leonardi","year":"2019","unstructured":"Leonardi, A. et al. A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis: the VEKTIS Study. Ophthalmology 126, 671\u2013681 (2019).","journal-title":"Ophthalmology"},{"key":"85256_CR30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/ACI.0b013e3282efb726","volume":"7","author":"S Bonini","year":"2007","unstructured":"Bonini, S., Sacchetti, M., Mantelli, F. & Lambiase, A. Clinical grading of vernal keratoconjunctivitis. Curr. Opin. Allergy Clin. Immunol. 7, 436\u2013441 (2007).","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"85256_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/jamaophthalmol.2023.0709","volume":"141","author":"EK Akpek","year":"2023","unstructured":"Akpek, E. K. et al. Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe Dry Eye Disease: the ESSENCE-2 Randomized Clinical Trial. JAMA Ophthalmol. 141, 459\u2013466 (2023).","journal-title":"JAMA Ophthalmol."},{"key":"85256_CR32","doi-asserted-by":"crossref","unstructured":"Baudouin, C. et al. A randomized study of the efficacy and safety of 0.1% cyclosporine a cationic emulsion in treatment of moderate to severe dry eye. Eur. J. Ophthalmol. 27, 520\u2013530","DOI":"10.5301\/ejo.5000952"},{"key":"85256_CR33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s12325-009-0037-2","volume":"26","author":"BA Schechter","year":"2009","unstructured":"Schechter, B. A., Katz, R. S. & Friedman, L. S. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv. Ther. 26, 651\u2013659 (2009).","journal-title":"Adv. Ther."},{"key":"85256_CR34","doi-asserted-by":"crossref","unstructured":"Nebbioso, M. et al. Analysis of the pathogenic factors and management of Dry Eye in Ocular Surface disorders. Int. J. Mol. Sci. 18 (2017).","DOI":"10.20944\/preprints201705.0161.v1"},{"key":"85256_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40123-013-0019-y","volume":"2","author":"A Leonardi","year":"2013","unstructured":"Leonardi, A. Management of vernal keratoconjunctivitis. Ophthalmol. Ther. 2, 73\u201388 (2013).","journal-title":"Ophthalmol. Ther."},{"key":"85256_CR36","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1055\/a-1556-1182","volume":"239","author":"J Biermann","year":"2022","unstructured":"Biermann, J., Bosche, F., Eter, N. & Beisse, F. Treating severe Pediatric Keratoconjunctivitis with Topical Cyclosporine A. Klin. Monbl Augenheilkd. 239, 1374\u20131380 (2022).","journal-title":"Klin. Monbl Augenheilkd"},{"key":"85256_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/jop.2008.0103","volume":"25","author":"N Ebihara","year":"2009","unstructured":"Ebihara, N. et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J. Ocul Pharmacol. Ther. 25, 365\u2013372 (2009).","journal-title":"J. Ocul Pharmacol. Ther."},{"key":"85256_CR38","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/bjophthalmol-2020-318092","volume":"106","author":"R Deshmukh","year":"2022","unstructured":"Deshmukh, R. et al. Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases. Br. J. Ophthalmol. 106, 1087\u20131092 (2022).","journal-title":"Br. J. Ophthalmol."},{"key":"85256_CR39","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0181-5512(07)91357-1","volume":"30","author":"S Doan","year":"2007","unstructured":"Doan, S. et al. [Efficacy of topical 2% cyclosporine A as a steroid-sparing agent in steroid-dependent vernal keratoconjunctivitis]. J. Fr. Ophtalmol. 30, 697\u2013701 (2007).","journal-title":"J. Fr. Ophtalmol"},{"key":"85256_CR40","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s40123-023-00707-y","volume":"12","author":"G Giannaccare","year":"2023","unstructured":"Giannaccare, G. et al. Clinical outcomes of topical 0.1% ciclosporin Cationic Emulsion used on label in children with Vernal Keratoconjunctivitis. Ophthalmol. Ther. 12, 1787\u20131793 (2023).","journal-title":"Ophthalmol. Ther."},{"key":"85256_CR41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3928\/01913913-20220420-03","volume":"59","author":"DG Ghiglioni","year":"2022","unstructured":"Ghiglioni, D. G. et al. Cyclosporine a 0.1% Cationic Emulsion in Vernal Keratoconjunctivitis. J. Pediatr. Ophthalmol. Strabismus. 59, 279 (2022).","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"85256_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1350-9462(01)00017-9","volume":"21","author":"TF Vandamme","year":"2002","unstructured":"Vandamme, T. F. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 21, 15\u201334 (2002).","journal-title":"Prog Retin Eye Res."},{"key":"85256_CR43","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/ICU.0000000000000167","volume":"26","author":"KM Hammersmith","year":"2015","unstructured":"Hammersmith, K. M. Blepharokeratoconjunctivitis in children. Curr. Opin. Ophthalmol. 26, 301\u2013305 (2015).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"85256_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jtos.2022.04.004","volume":"25","author":"AH Dahlmann-Noor","year":"2022","unstructured":"Dahlmann-Noor, A. H. et al. A 1\u00a0mg\/ml in pediatric blepharokeratoconjunctivitis: Case series of 145 children and young people. Ocul Surf. 25, 37\u201339 (2022).","journal-title":"Ocul Surf."},{"key":"85256_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","volume":"47","author":"S Matsuda","year":"2000","unstructured":"Matsuda, S. & Koyasu, S. Mechanisms of action of cyclosporine. Immunopharmacology 47, 119\u2013125 (2000).","journal-title":"Immunopharmacology"},{"key":"85256_CR46","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2165\/00003495-199345060-00007","volume":"45","author":"D Faulds","year":"1993","unstructured":"Faulds, D., Goa, K. L. & Benfield, P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45, 953\u20131040 (1993).","journal-title":"Drugs"},{"key":"85256_CR47","doi-asserted-by":"publisher","first-page":"472","DOI":"10.2165\/00003088-199324060-00004","volume":"24","author":"A Fahr","year":"1993","unstructured":"Fahr, A. Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet. 24, 472\u2013495 (1993).","journal-title":"Clin. Pharmacokinet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85256-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85256-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85256-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T12:00:09Z","timestamp":1739016009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85256-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["85256"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-85256-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study design followed the tenets of the Declaration of Helsinki for biomedical research in human subjects, and the procedures were approved by the ethics committee of the National Healthcare Service Center (KRID: 648905308,) and by the National Center for Public Health and Pharmacy (registration number OGY\u00c9I\/79707-1\/2022).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"4671"}}